The long-term risk of smoking in diabetic patients with stable ischemic heart disease treated with intensive medical therapy and lifestyle modification

被引:8
|
作者
Khan, Asrar A. [1 ]
Chung, Matthew J. [2 ]
Novak, Eric [2 ]
Brooks, Maria Mori [3 ]
Brown, David L. [2 ]
机构
[1] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Div Cardiovasc, Campus Box 8086,660 S Euclid Ave, St Louis, MO 63110 USA
[3] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA
关键词
Stable ischemic heart disease; diabetes; smoking; outcomes; PERCUTANEOUS CORONARY INTERVENTION; BARI 2D TRIAL; 5-YEAR FOLLOW-UP; CARDIOVASCULAR-DISEASE; CLINICAL-OUTCOMES; SYNTAX TRIAL; REVASCULARIZATION; CESSATION; PREVENTION; MANAGEMENT;
D O I
10.1177/2047487317711046
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction The long-term risk of smoking in diabetic patients with stable ischemic heart disease (SIHD) is unknown. We sought to analyze the impact of smoking on outcomes of diabetic patients with SIHD when other cardiovascular risk factors are being aggressively treated. Methods The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial randomized 2368 diabetics with SIHD to intensive medical therapy (IMT) with prompt revascularization or IMT alone. Smoking status was obtained at baseline, 6 months, and 1, 2, 3, 4 and 5 years. The primary endpoint of interest was all-cause mortality. Results Of 2360 patients, 33.1% of patients never smoked, 54.4% were former smokers, and 12.5% were current smokers. The rate of all-cause mortality was greater for current (2.5 deaths/100 patient-years) and former smokers (3.1 deaths/100 patient-years) than never smokers (2.1 deaths/100 patient-years) (P=0.007). Cardiac death, cardiovascular death, fatal or nonfatal myocardial infarction, and fatal or nonfatal stroke were not increased in current or former smokers compared with never smokers. Compared with never smokers, current smokers experienced a 49% increased hazard of death (Hazard Ratio (HR) 1.49, 95% Confidence Interval (CI): 0.97-2.29, P=0.07) whereas former smokers had a 37% increased hazard of death (HR 1.37, 95% CI: 1.04-2.79, P=0.02) when considering smoking status as a time-dependent variable and adjusting for factors that differed by smoking status. Conclusions Current and former smoking are associated with increased all-cause mortality in diabetics with SIHD but not with increased cardiovascular morbidity or mortality.
引用
收藏
页码:1506 / 1514
页数:9
相关论文
共 50 条
  • [41] Dual Antiplatelet Therapy in Patients with Stable Ischemic Heart Disease
    Keach, Joseph Walker
    Yeh, Robert W.
    Maddox, Thomas M.
    CURRENT ATHEROSCLEROSIS REPORTS, 2016, 18 (01)
  • [42] Dual Antiplatelet Therapy in Patients with Stable Ischemic Heart Disease
    Joseph Walker Keach
    Robert W. Yeh
    Thomas M. Maddox
    Current Atherosclerosis Reports, 2016, 18
  • [43] Long-term trajectories of anxiety and depression in patients with stable coronary heart disease and risk of subsequent cardiovascular events
    Peter, Raphael S.
    Meyer, Michelle L.
    Mons, Ute
    Schoettker, Ben
    Keller, Ferdinand
    Schmucker, Roman
    Koenig, Wolfgang
    Brenner, Hermann
    Rothenbacher, Dietrich
    DEPRESSION AND ANXIETY, 2020, 37 (08) : 784 - 792
  • [44] Hyperhomocysteinemia is a risk factor for ischemic heart disease in diabetic patients
    Okada, E
    Oida, K
    Tada, H
    Asazuma, K
    Kohno, M
    Tohda, G
    Miyamori, I
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 164 - 164
  • [45] Long-Term Outcomes of Ischemic Stroke Patients with Concurrent Intracranial and Extracranial Stenoses and Ischemic Heart Disease
    Man, B. L.
    Fu, Y. P.
    Chan, Y. Y.
    Lam, W.
    Hui, C. F.
    Leung, W. H.
    Mok, V.
    Wong, K. S.
    CEREBROVASCULAR DISEASES, 2010, 29 (03) : 236 - 241
  • [46] Mortality risk of long-term amiodarone therapy for atrial fibrillation patients without structural heart disease
    Qin, Dingxin
    Leef, George
    Alam, Mian Bilal
    Rattan, Rohit
    Munir, Mohamad Bilal
    Patel, Divyang
    Khattak, Furqan
    Adelstein, Evan
    Jain, Sandeep K.
    Saba, Samir
    CARDIOLOGY JOURNAL, 2015, 22 (06) : 622 - 629
  • [47] EFFECTS OF LONG-TERM GALLOPAMIL IN ISCHEMIC-HEART-DISEASE
    PAZZOLA, A
    TONOLO, G
    TROFFA, C
    BACCIU, S
    PARPAGLIA, PP
    PATTERI, G
    PIGA, G
    MAMELI, P
    GIRAUDI, D
    PALA, F
    MAIOLI, M
    GITTI, M
    DIGIOVANNA, F
    GLORIOSO, N
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1990, 48 (06): : 1030 - 1035
  • [48] RISK FACTOR CONTROL, LIFESTYLE MODIFICATION, AND GUIDELINE-DIRECTED MEDICAL THERAPY IN PATIENTS WITH CARDIOVASCULAR DISEASE
    Kadosh, Bernard
    Vaidean, Georgeta
    Berger, Jeffrey
    Garshick, Michael
    Gianos, Eugenia
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 1854 - 1854
  • [49] LONG-TERM EFFICACY OF RAPID SMOKING THERAPY IN SMOKERS WITH PULMONARY AND CORONARY HEART-DISEASE
    SACHS, DPL
    HALL, RG
    HALL, SM
    SACHS, BL
    BENOWITZ, N
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1983, 127 (04): : 115 - 115
  • [50] Effect of long-term enduracin monotherapy on clinicobiochemical characteristics of patients with ischemic heart disease
    Kukharchuk, VV
    Solovyev, EY
    Malyshev, PP
    Rozhkova, TA
    Semenova, OA
    Aronskaya, EE
    TERAPEVTICHESKII ARKHIV, 1997, 69 (09) : 41 - 45